Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products. Alcon’s shares made their debut on the ...

Novartis bought Alcon from Nestlé for $52 billion in 2011, as CEO Joe Jimenez, guided by then chairman Vasella, sought to build the company into a European healthcare business following the model ...

ZURICH (Reuters) - Novartis AG wrapped up its long-awaited buyout of the remainder of U.S.-listed eyecare group Alcon Inc for $12.9 billion, after sweetening its original offer with cash. The Swiss ...

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments ...